Epizyme Up on Milestone Payments - Analyst Blog


Shutterstock photo

Shares of Epizyme, Inc . ( EPZM ) were up 75.6% a day after the company announced the achievement of the proof of concept (POC) milestone in the development program of its pipeline candidate EPZ-5676 in an ongoing phase I study.

Epizyme is developing the candidate for treating a rare form of acute leukemia characterized by a re-arranged MML gene (mixed lineage leukemia). The re-arrangement is caused by chromosomal translocation. We note that Epizyme is developing EPZ-5676 in collaboration with Celgene Corporation ( CELG ) which holds the license for EPZ-5676 outside the U.S.

The achievement led to Epizyme earning a milestone payment of $25 million, triggered by objective responses in patients with translocations of the MLL gene (MLL-r). These patients are currently enrolled in the fourth dose cohort in the dose escalation stage of the ongoing phase I trial.

Epizyme expects to present data from this phase I study on EPZ-5676, in 2014 including the dose escalation stage that is fully enrolled and the adult MLL-r expansion stage which is currently enrolling patients.

We remind investors that EPZ-5676 enjoys orphan drug status in the U.S. since May 2013. Meanwhile, the European Medicines Agency's Committee for Orphan Medicinal Products recommended orphan drug designation for EPZ-5676 to the European Commission in Dec 2013.

In addition, Epizyme earned a $4 million milestone payment for one of the three histone methyltransferase (HMT) targets, which are included in the company's collaboration agreement with GlaxoSmithKline ( GSK ).

The total milestone payments from  Celgene and GlaxoSmithKline is expected to boost the estimated 2013 end cash and account receivables balance to approximately $145 million, up from the previous guidance of $115 million.

Going forward, Epizyme expects to have as many as five clinical POC programs in 2014. These include the ongoing adult MLL-r expansion stage, MLL-r in pediatric patients, and adult MLL-PTD patients on EPZ-5676. Additionally, the POC program includes indications like adult non-Hodgkin lymphoma patients and pediatric and young adult patients with synovial sarcomas on candidate EPZ-6438.

Epizyme, a clinical stage biopharmaceutical company, carries a Zacks Rank #3 (Hold). At current levels, Affymetrix Inc. ( AFFX ) looks attractive with a Zacks Rank #1 (Strong Buy).

AFFYMETRIX INC (AFFX): Free Stock Analysis Report

CELGENE CORP (CELG): Free Stock Analysis Report

EPIZYME INC (EPZM): Free Stock Analysis Report

GLAXOSMITHKLINE (GSK): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: Investing , Business , Stocks
Referenced Stocks: AFFX , CELG , EPZM , GSK

More from Zacks.com




Equity Research
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by BankRate.com